PureTech Health (PRTC)
(Delayed Data from NSDQ)
$27.89 USD
-0.61 (-2.14%)
Updated Apr 30, 2024 03:10 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for PureTech Health PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 16 | 17 | 12 | 10 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 3 | 16 | 17 | 12 | 10 |
Selling & Adminstrative & Depr. & Amort Expenses | 150 | 213 | 168 | 131 | 145 |
Income After Depreciation & Amortization | -146 | -198 | -150 | -120 | -135 |
Non-Operating Income | 120 | 105 | 91 | 139 | 614 |
Interest Expense | 10 | 0 | 0 | 0 | 0 |
Pretax Income | -36 | -93 | -59 | 19 | 478 |
Income Taxes | 31 | -56 | 4 | 14 | 112 |
Minority Interest | -1 | 13 | -2 | -1 | -55 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -67 | -37 | -63 | 5 | 366 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -66 | -50 | -61 | 6 | 421 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -141 | -189 | -143 | -113 | -129 |
Depreciation & Amortization (Cash Flow) | 5 | 9 | 7 | 7 | 7 |
Income After Depreciation & Amortization | -146 | -198 | -150 | -120 | -135 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 276.30 | 284.76 | NA | 292.86 | NA |
Diluted EPS Before Non-Recurring Items | -0.24 | -0.18 | NA | 0.02 | NA |
Diluted Net EPS (GAAP) | -2.40 | -1.80 | -0.21 | 0.02 | NA |
Fiscal Year end for PureTech Health PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -99,999.00 | -99,999.00 | NA | NA | NA |
Diluted Net EPS (GAAP) | -99,999.00 | -99,999.00 | NA | NA | NA |